Literature DB >> 7033844

Nicotine binding sites and their localization in the central nervous system.

B R Martin, M D Aceto.   

Abstract

The resolution of racemic nicotine to provide optically pure (+)-nicotine and the synthesis of radiolabeled nicotine with high specific activity have facilitated the study of nicotine binding in brain. The actions of the stereoisomers of nicotine on the central nervous system are qualitatively similar in most tests but (-)-nicotine is more potent than the unnatural (+)-isomer by 10-fold or greater. Binding of radiolabeled nicotine to brain has both saturable and nonsaturable components. Only saturable binding is affected by incubation conditions such as time, temperature, pH and ion concentration. Excess concentrations of the stereoisomers are equally effective in displacing (-)-[3H]-nicotine from brain homogenates. Nevertheless, a direct comparison of (+)-[3H]-nicotine and (-)-[3H]-nicotine binding shows that the latter has a KD three times lower than the former. (-)-[3H]-Nicotine is bound to the greatest degree in hypothalamus and hippocampus, areas that also exhibited the most stereoselectivity for nicotine. However, differences in the binding affinities of the two isomers were far less than the pharmacological stereospecificity observed.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7033844     DOI: 10.1016/0149-7634(81)90017-8

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  11 in total

Review 1.  Neuropharmacology of the interoceptive stimulus properties of nicotine.

Authors:  Thomas E Wooters; Rick A Bevins; Michael T Bardo
Journal:  Curr Drug Abuse Rev       Date:  2009-09

2.  Hippocampal Interneuronal α7 nAChRs Modulate Theta Oscillations in Freely Moving Mice.

Authors:  Zhenglin Gu; Kathleen G Smith; Georgia M Alexander; Inês Guerreiro; Serena M Dudek; Boris Gutkin; Patricia Jensen; Jerrel L Yakel
Journal:  Cell Rep       Date:  2020-06-09       Impact factor: 9.423

3.  Brain sites involved in the mediation of the behavioral effects of intraventricularly administered (-)-nicotine.

Authors:  V J DeNoble; P C Mele
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Depression impairs learning, whereas the selective serotonin reuptake inhibitor, paroxetine, impairs generalization in patients with major depressive disorder.

Authors:  Mohammad M Herzallah; Ahmed A Moustafa; Joman Y Natsheh; Omar A Danoun; Jessica R Simon; Yasin I Tayem; Mahmud A Sehwail; Ivona Amleh; Issam Bannoura; Georgios Petrides; Catherine E Myers; Mark A Gluck
Journal:  J Affect Disord       Date:  2013-08-13       Impact factor: 4.839

5.  Behavioural and biochemical evidence for interactions between Delta 9-tetrahydrocannabinol and nicotine.

Authors:  Emmanuel Valjent; Jennifer M Mitchell; Marie-Jo Besson; Jocelyne Caboche; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

6.  A comparison of the binding of nicotine and nornicotine stereoisomers to nicotinic binding sites in rat brain cortex.

Authors:  J R Copeland; A Adem; P Jacob; A Nordberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-02       Impact factor: 3.000

7.  Antinociceptive effects of the stereoisomers of nicotine given intrathecally in spinal rats.

Authors:  M K Christensen; D F Smith
Journal:  J Neural Transm Gen Sect       Date:  1990

8.  Isolation of a nicotine binding site from rat brain by affinity chromatography.

Authors:  L G Abood; W Latham; S Grassi
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

9.  In vitro binding of 3H-acetylcholine to nicotinic receptors in rodent and human brain.

Authors:  C Larsson; P A Lundberg; A Halén; A Adem; A Nordberg
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

Review 10.  The "stop" and "go" of nicotine dependence: role of GABA and glutamate.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Cold Spring Harb Perspect Med       Date:  2013-06-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.